Endocrine Disruption Analysis Service
When drugs interfere with the endocrine system, they may cause developmental abnormalities, reproductive disorders, increased risk of cancer abnormal immune function and impaired nervous system function. Sex hormone levels are most often affected.
Creative Biolabs is a leading biotechnology services platform, providing pre-clinical efficacy evaluation technology. Based on the reliable drug safety evaluation system, Creative Biolabs is committed to creating a one-stop technical service platform about endocrine disruption, carrying out assessment and integrated technical services for the new drug research and development team. Creative Biolabs will continue to carry out technological innovation and introduce domestic and foreign advanced technology and experimental platform, to provide more comprehensive technical support for the partners.
We provide but are not limited to:
- The estrogen receptor binding assay. The goal of the estrogen receptor binding assay is to identify drugs that have the potential interaction with the estrogen receptor (ER) in vitro. Rat uterine cytosol is used to study whether drugs can interact with ERs prepared from rat uterine cytosol by displacing the endogenous hormone 17β-estradiol. The hormone binding domain of the ER is highly conserved across species. Hence substances binding the ER from rats are supposed to be able to bind the ER in humans.
- The estrogen receptor binding assay studies the competitive inhibition of binding of labeled estradiol to rat ER by test samples. The assay covers two sets of experiments: (1) The Saturation Binding Experiment; (2) The competitive Binding Experiment. Each experiment includes three runs and each run consists of three replicates at each concentration.
- The androgen receptor binding assay. The androgen receptor binding assay makes sure drugs that have the potential interaction with the androgen receptor (AR) in vitro. The biological action of androgens is mediated by the interaction with AR. When androgens are combined with AR, AR dimerization occurs, causing a series of physiological changes. AR isolated from rat ventral prostates is used in this assay. In the mammalian phylogenetic lines, DNA sequence is highly conserved. Consequently, substances binding the AR from rats are supposed to be able to bind the AR in humans. This assay can't differentiate agonist and antagonist activity, in spite of it can identify drugs that compete for AR binding.
- In OCSPP Guideline 890.1150, the androgen receptor binding assay is defined as a radioligand binding assay. The assay contains two sets of experiments: (1) The saturation binding experiment; (2) The competitive binding experiment. Each experiment contains three runs and each run consists of three replicates at each concentration.
- The estrogen receptor transcriptional activation (ERTA) assay. The ERTA assay ascertains compositions which bind and activate the estrogen receptor (ER) in vitro. In vitro transcriptional activation (TA) assay can simulate the process that estrogen interacts with ER to regulate the expression of specific genes. Using cells specially designed to consist of an ERE promoter linked to a reporter gene, the gene product that can be easily measured can produce. In addition, the DNA construct is also introduced into the cell to express the ER protein in some cases.
- Under the standard cell culture condition, the ERTA assay is carried out in 96-well plate. After attaching for 3 hours, the cells are exposed to a variety of concentrations of the test chemical (in three repeated wells) for 20-24 hours. Then the medium is removed and the cells are lysed. After added the luciferin substrate, the luminometer can measure luciferase activity.
The popular services：
- High-throughput screening (HTS) and high-content screening (HCS) platform is a widely used technique in the early stage of drug development and can be applied to many aspects of compound detection. Its main advantage is that it can screen a large number of samples at the same time and provide information with reference value quickly. High-throughput toxicity screening and high-content toxicity screening can simultaneously detect the endocrine disrupting effects of a large number of compounds.
With a variety of advanced equipment and years of practical experience in HTS/HCS, the Creative Biolabs can provide comprehensive screening solutions, carrying out a variety of screening services on drug toxicity about endocrine disruption efficiently and quickly.
Advantages of endocrine disruption detection services:
- Obtaining higher quality experimental data.
- Continuous technological innovation.
- The world's leading experiment platform.
- Comprehensive results analysis and mechanism research.
References
- Usami M, et al. Estrogen receptor binding assay of chemicals with a surface plasmon resonance biosensor. J Steroid Biochem Mol Biol. 2002, 81(1):47–55.
- Guo H, et al. Androgen receptor binding to an androgen-responsive element in the promoter of the Srsf4 gene inhibits its expression in mouse Sertoli cells. Mol Reprod Dev. 2015, 82(12):976–985.
- Xin QL, et al. Transcriptional activation of nuclear estrogen receptor and progesterone receptor and its regulation. Sheng Li Xue Bao. 2016, 68(4):435–454.
- Shuai Z L, et al. Review of high-content screening applications in toxicology. Archives of Toxicology, 2019, 93(12): 3387-3396.
*For Research Use Only. Not for use in diagnostic procedures.
